Growing Demand for Fast-Acting Diabetes Management Solutions Accelerates Market Growth – Renub Research
According to a newly released study by Renub Research, the Global Rapid Acting Insulin Market was valued at USD 7.71 billion in 2024 and is forecast to reach USD 11.77 billion by 2033, growing at a CAGR of 4.81% between 2025 and 2033. The rising incidence of diabetes, coupled with the demand for efficient and timely glucose regulation therapies, is driving significant investment and innovation in the global rapid acting insulin space.
👉 Explore Full Report on Rapid Acting Insulin Market
Rapid acting insulin, also known as fast-acting or mealtime insulin, is a crucial therapeutic category for people with diabetes. It begins to work within 15 minutes of injection, peaks in about an hour, and continues to be effective for two to four hours. These characteristics make it ideal for postprandial glucose control—a growing concern among diabetic patients and healthcare professionals.